Medullary thyroid carcinoma history: an absolute contraindication because of the preclinical findings in rodent toxicology. The history (personal or family, especially multiple endocrine neoplasia type 2) is an important screening question.
Second pass at: Pregnancy and pregnancy planning: contraindication and washout posts 121–128
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
post #122 answers the question as asked. The question underneath it is different.
Disordered eating history: a history of anorexia nervosa, bulimia, or other eating disorders changes the risk-benefit calculation because appetite suppression might trigger relapse. This population requires specialist input.
On post #120 — agreed on the reasoning, with one qualification.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Hepatic impairment: less is known about dosing in significant liver disease than in kidney disease. Extreme caution applies because the liver metabolises a large fraction of many medications.
post #126 is right about the mechanism and I think understates the practical bit.
Adolescents: a distinct evidence base exists. The compounds are not approved for routine adolescent obesity but are being studied. Adolescent physiology and psychology differ from adults' in ways that matter for this medication class.
Renal impairment: the compounds are cleared renally to some degree. Dose adjustments might be needed in severe renal impairment. Consulting with a clinician familiar with renal dosing is prudent.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Adolescents: a distinct evidence base — one year on
Posting this under the heading it deserves: Adolescents: a distinct evidence base — one year on Everything below is what sits behind that. General question, not a request for advice about my own care — I know…
|
+78 | 88 | 9.3k | 3mo |
|
[2026 update] People with a low starting BMI: where the evidence stops
People with a low starting BMI: where the evidence stops Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
+19 | 23 | 62k | 23mo |
|
Athletes in weight-category sports: a different risk calculus — a second dataset
On the subject in the title: Athletes in weight-category sports: a different risk calculus — a second dataset Working notes rather than a conclusion. General question, not a request for advice about my own…
|
+37 | 41 | 16k | 20mo |
|
Renal impairment: what the labelling says about dose
On the subject in the title: Renal impairment: what the labelling says about dose Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference…
|
4 | 8.9k | 19mo | |
|
Type 1 diabetes: off-label use and the evidence gap
On the subject in the title: Type 1 diabetes: off-label use and the evidence gap Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference…
|
2 | 2.3k | 1d |
Related topics — sharing the tags chronic kidney disease, disordered eating, older adults
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
History of disordered eating and why it changes the conversation
History of disordered eating and why it changes the conversation Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+20 | 24 | 30k | 8mo |
|
Gastro-oesophageal reflux: improving or worsening?
The question in the title: Gastro-oesophageal reflux: improving or worsening? I will give what I have already checked below so nobody repeats it. Asking about a population rather than about a person. The…
|
+54 | 58 | 8.2k | 1mo |
|
Food noise reducing and the disorientation that can follow
Posting this under the heading it deserves: Food noise reducing and the disorientation that can follow Everything below is what sits behind that. General question, not a request for advice about my own care —…
|
+40 | 45 | 8.9k | 20mo |
|
Type 1 diabetes: off-label use and the evidence gap
On the subject in the title: Type 1 diabetes: off-label use and the evidence gap Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference…
|
2 | 2.3k | 1d | |
|
Older adults, sarcopenia risk, and the trade-off nobody quantifies — does this still hold?
Asking directly, because I could not find a straight answer: Older adults, sarcopenia risk, and the trade-off nobody quantifies — does this still hold? General question, not a request for advice about my own…
|
2 | 22k | 11mo |